A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery

International Journal of Cancer

Volumn 136, Issue 8, 2015, Pages 1976-1984

  Park, Yeon Hee ^a   Jung, Hae Hyun ^a   Do, In Gu ^a,b   Cho, Eun Yoon ^a   Sohn, Insuk ^a   Jung, Sin Ho ^a   Kil, Won Ho ^a   Kim, Seok Won ^a   Lee, Jeong Eon ^a   Nam, Seok Jin ^a   Ahn, Jin Seok ^a   Im, Young Hyuck ^a  

^a Sungkyunkwan University   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Chemotherapy; Expression assay; Prognostic factor; Triple negative breast cancer

Indexed keywords

MESSENGER RNA; PROTEIN MDMX; SMAD2 PROTEIN; TRANSCRIPTOME; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; ETV6 GENE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HRAS GENE; HUMAN; HUMAN TISSUE; KRT6A GENE; MAJOR CLINICAL STUDY; MDM4 GENE; NFKB1 GENE; RECURRENCE FREE SURVIVAL; SMAD2 GENE; SURVIVAL RATE; SURVIVAL TIME; TP63 GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GENE; ADJUVANT CHEMOTHERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR RECURRENCE;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TRANSCRIPTOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922513788     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29233     Document Type: Article

References (30)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
3. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
4. Zhao H, Langerod A, Ji Y, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 2004;15:2523-36.
5. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007;110:876-84.
6. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008;123:236-40.
7. Kreike B, Van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
8. Rakha E, Ellis I, Reis-Filho J. Are triple-negative and basal-like breast cancer synonymous? Clin Cancer Res 2008;14:618.
9. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
10. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 2012;486:395-9.
11. O'Shaughnessy JSL, Danso MA. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011;29: Abstract 1007.
12. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-53.
13. Moiseyenko VM, Protsenko SA, Brezhnev NV, et al. High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases. Cancer Genet Cytogenet 2010;197:91-4.
14. Tutt A, Robson M, Garber JE, et al. Oral poly (-ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44.
15. Mell LK, Dignam JJ, Salama JK, et al. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol 2010;28:15-20.
16. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34.
17. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
18. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
19. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
20. Network NCC. Invasive Breast Cancer. NCCN clinical practice guidelines in oncology 2014: BINV-8.
21. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
22. Sohn I, Kim J, Jung SH, Park C. Gradient lasso for Cox proportional hazards model. Bioinformatics 2009;25:1775-81.
23. Pang H, Jung SH. Sample size considerations of prediction-validation methods in highdimensional data for survival outcomes. Genet Epidemiol 2013;37:276-82.
24. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-72.
25. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229-35.
26. Harrell FE, Jr., Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. JAMA 1982;247:2543-6.
27. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
28. Park YH, Lee SJ, Cho EY, et al. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol 2011;22:1554-60.
29. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
30. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-7.